If you have been seeing red light therapy come up in conversations about eye health, you are probably wondering whether it is real science or just hype. The honest answer is both, depending on the condition and how far along the research is.
Red light therapy for eyes, also called photobiomodulation or PBM, uses low levels of red and near-infrared light to help cells in the eye work better. Scientists have been studying it for conditions ranging from age-related macular degeneration to childhood nearsightedness to diabetic eye disease. In some of those areas, the evidence is strong enough that the FDA has already authorized a treatment. In others, researchers are still gathering data.
So what can red light therapy for eyes actually do? Here is what the science says right now.
First, How Does It Work?
Before getting into what it can do, it helps to understand why red light would affect the eyes at all.
The main target is the mitochondria, which are the energy-producing parts of your cells. Inside the mitochondria is a protein called cytochrome c oxidase. Research reviewed in PMC explains that red and near-infrared light primarily targets this protein, which boosts energy metabolism and ATP production. ATP is the fuel your cells run on.
The retina has one of the highest energy demands of any tissue in the body. That makes it especially sensitive to drops in mitochondrial function, and especially responsive to anything that supports it. A 2025 protocol published in Systematic Reviews through Springer Nature describes PBM as a strategy that uses low-level red or near-infrared light to regulate cellular energy, reduce oxidative stress, and modulate inflammation. Those three things sit at the root of many eye conditions that get worse with age.
This is not laser eye surgery or UV light exposure. It is low-level, non-thermal, and non-invasive. A foundational review published in PMC noted that the non-invasive nature of PBM, combined with promising clinical reports and preclinical animal studies, positions it as a strong candidate for treating a wide range of retinal disorders.
What It Can Do: The Strongest Evidence
Slow the Progression of Dry AMD
Age-related macular degeneration, or AMD, is one of the leading causes of blindness in older adults. The dry form involves a buildup of protein deposits called drusen under the retina that gradually damages the cells responsible for sharp central vision. There is no cure for dry AMD, and until recently, there were very few treatment options.
This is where red light therapy has its strongest track record. A narrative review in Ophthalmology and Therapy confirmed that photobiomodulation is approved by both the FDA and the European Medicines Agency for the treatment of intermediate AMD.
The evidence behind that approval comes largely from the LIGHTSITE III trial, a randomized controlled study. Results published in PubMed showed that multiwavelength PBM produced a gain of 6.2 letters in best-corrected visual acuity at 21 months, and the rate of disease progression to geographic atrophy was significantly lower in treated eyes at 6.8% compared to 24.0% in sham-treated eyes.
To be fair about what the numbers mean: a clinical analysis from Ophthalmology Advisor noted that the visual acuity improvement, while statistically significant, falls below the 15-letter gain typically considered clinically meaningful by regulatory standards, and the treatment did not show clear superiority in secondary measures like contrast sensitivity or reading performance. The results are real, especially for slowing disease progression, but they are not a dramatic reversal of vision loss.
Slow Myopia Progression in Children
Myopia, or nearsightedness, is getting more common in children worldwide. Researchers have been studying repeated low-level red light therapy as a way to slow how fast it worsens.
A multicenter randomized controlled trial published in PubMed followed children ages 8 to 13 with myopia. Over 12 months, the red light therapy group had significantly less axial elongation (0.13 mm vs. 0.38 mm in controls) and significantly slower progression overall. No severe adverse events were reported.
A meta-analysis published in PMC covered six randomized controlled trials and 820 eyes and found consistent results across studies. This is one of the more reliably supported areas of red light therapy for eyes research so far.
What It Shows Promise For: Early, but Encouraging
Supporting Diabetic Retinopathy Treatment
Diabetic retinopathy is damage to the blood vessels in the retina caused by high blood sugar over time. It is a leading cause of vision loss in working-age adults.
A comprehensive review published in PMC found that clinical trials have shown PBM can improve treatment outcomes in diabetic retinopathy, with patients reporting reduced retinal inflammation and improvements in visual acuity. A 2024 overview published in Frontiers in Ophthalmology reported reductions in central retinal thickness and resolution of intraretinal fluid after PBM treatment. The evidence is early stage, and larger trials are still needed, but the direction is positive.
Easing Dry Eye Symptoms
Dry eye is one of the most common eye complaints. The same comprehensive PMC review found that patients undergoing PBM reported improvements in tear film stability, suggesting a role for red light as a supportive treatment for dry eye alongside standard care. Active clinical trials are currently comparing red versus blue wavelengths for dry eye and eyelid inflammation. This area is growing, but is not yet at the same level of evidence as AMD or myopia.
Protecting Against Glaucoma Damage
Glaucoma damages the optic nerve over time and is a leading cause of irreversible blindness. Research on red light therapy for glaucoma is still early, with studies exploring its potential to reduce intraocular pressure and protect optic nerve cells. A 2025 review in Graefe’s Archive for Clinical and Experimental Ophthalmology cited multiple studies exploring PBM as a potential supportive approach. More research is needed before it can be considered a standard option.
What It Cannot Do
Red light therapy for eyes cannot cure any eye condition. It is not a replacement for regular eye exams, prescribed medication, or treatment from an eye doctor. It also cannot undo existing damage to the retina or optic nerve.
A 2025 review in Graefe’s Archive for Clinical and Experimental Ophthalmology pointed out that questions around optimal dosing, safety, and standardization are still being worked out, and that long-term effects need careful evaluation. Most studies are still relatively small or short-term. The right wavelengths, session lengths, and treatment frequencies have not been fully settled across conditions.
The most honest framing is this: red light therapy for eyes can support eye health and slow certain types of damage in some conditions. It cannot reverse vision loss that has already happened, and it works best as part of a broader care plan, not as a standalone fix.
Is It Safe?
Based on clinical studies so far, red light therapy for eyes is well-tolerated when used correctly. A systematic review on safety published in ScienceDirect found that brief afterimages were the most commonly reported side effect, and they resolved with a short rest. No severe adverse events were reported across the reviewed trials. The LIGHTSITE III trial found a favorable safety profile with no signs of phototoxicity over 24 months.
A few things to keep in mind:
- Do not look directly into bright light sources or use devices not designed for ocular use
- Consumer red light panels made for skin are not the same as devices studied for eye applications
- Anyone with an existing eye condition should check with their eye doctor before trying any red light therapy near the eyes
The Bottom Line
Red light therapy for eyes can slow the progression of dry AMD, reduce how fast myopia worsens in children, and shows early promise for diabetic retinopathy, dry eye, and glaucoma. The FDA has authorized photobiomodulation for intermediate dry AMD, which is a meaningful signal that this is not fringe science.
What it cannot do is cure eye disease, replace standard care, or undo damage that has already occurred. The research is real and growing, and so are the questions still being answered.
If you’re ready to jump on the red light therapy bandwagon, find the right device for you by checking out our brand reviews or using our comparison tool.